Excellent response to therapeutic plasma exchange in myasthenia gravis patients irrespective of antibody status.


Journal

Journal of clinical apheresis
ISSN: 1098-1101
Titre abrégé: J Clin Apher
Pays: United States
ID NLM: 8216305

Informations de publication

Date de publication:
Aug 2019
Historique:
received: 01 05 2018
revised: 30 11 2018
accepted: 03 12 2018
pubmed: 20 2 2019
medline: 16 1 2020
entrez: 20 2 2019
Statut: ppublish

Résumé

The primary objective of this study was to assess response to plasma exchange (PLEX) in myasthenia gravis (MG) patients with and without autoantibodies (Ab) to acetylcholine receptor (AChR) or muscle-specific kinase (MuSK). Analysis was also done to determine if correlation existed between sex, early or late onset MG, thymoma, or thymectomy and response to PLEX. Data was analyzed on 58 consecutive MG patients treated with PLEX. Responses were categorized as complete response, clinical improvement requiring maintenance PLEX, or no/minimal response to PLEX. Eighty-eight percent (51/58) of patients were Ab-positive; 44 had AChR and 7 had MuSK Ab. Complete response was seen in 26 patients (24 Ab+), 24 remain on maintenance PLEX (19 Ab+), and 2 had no/minimal response (both AChR Ab+). Ab status (P = 0.43), AChR Ab (P = 0.10), MuSK Ab (P = 0.45), early onset MG (P = 0.63), thymoma (P = 0.46), and thymectomy (P = 0.16) were not significantly associated with outcome. Patient sex did show significant association with outcome (P = 0.01), with men more likely to have complete response and women more likely to require maintenance. Late onset MG is significantly associated with higher likelihood of complete response (P = 0.03). Antibody titers declined after PLEX in 83% of patients with complete response, in whom pre- and post-PLEX titers were available (n = 6). In conclusion, our study showed 96% response rate to PLEX in MG; however, only patient gender and late onset MG were significantly associated with treatment response.

Identifiants

pubmed: 30779438
doi: 10.1002/jca.21694
doi:

Substances chimiques

Autoantibodies 0
Receptors, Cholinergic 0
MUSK protein, human EC 2.7.10.1
Receptor Protein-Tyrosine Kinases EC 2.7.10.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

416-422

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Auteurs

Amena Usmani (A)

Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas.

Laura Kwan (L)

Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas.

Dina Wahib-Khalil (D)

Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas.

Jaya Trivedi (J)

Department of Neurology, University of Texas Southwestern Medical Center, Dallas, Texas.

Sharon Nations (S)

Department of Neurology, University of Texas Southwestern Medical Center, Dallas, Texas.

Ravi Sarode (R)

Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH